4 RESULTS
COMMENT Firstly, I think these results are fantastic and show the possibilities of BBB-crossing immunotherapy. The big question I would have thought is, have the patients been cured? Moreover, or alternatively, if the patients had been treated in their 20s, 30s,
COMMENT Biological mechanisms in addition to the more-studied proteopathies can hypothetically lead to atrophy, and could be related here. Some clues from literature: Localized hypoxemia perhaps could be related to the immunotherapy response, e.g., Marchi et al.,
COMMENT Congratulations to Xiaoying and the Holtzman lab for this very thought-provoking paper. Perhaps there could be some ideas around crossing NOD-SCID mice with tauopathy mice? The NOD-SCID mouse model has a much-weakened adaptive immune response (less T and
COMMENT Curative treatments with low side effects are the most meaningful, gold-standard example being penicillin, etc. The best treatments in history improve the patient from their current condition, increasing their health from a baseline level. Slowing progres
